Related Experiment Video

Updated: Feb 9, 2026

Technique to Target Microinjection to the Developing Xenopus Kidney
11:29

Technique to Target Microinjection to the Developing Xenopus Kidney

Published on: May 3, 2016

12.1K

Targeting of BMI-1 with PTC-209 inhibits glioblastoma development

Yu Kong1,2, Chunbo Ai1, Feng Dong1

  • 1a Department of Cell Biology , Tianjin Medical University , Tianjin , China.

Cell Cycle (Georgetown, Tex.)
|June 12, 2018
PubMed

Insights

A novel BMI-1 inhibitor, PTC-209, effectively targets glioblastoma stem cells and tumor growth. This study offers proof-of-concept for BMI-1 inhibitors as a promising new glioblastoma therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Glioblastoma multiforme (GBM) is an aggressive brain tumor with limited treatment options.
  • The oncogene BMI-1 (Polycomb Repressive Complex 1 component) is crucial in cancer development and a potential therapeutic target.
  • BMI-1 is highly expressed in GBM, particularly in glioblastoma stem cells (GSCs).

Purpose of the Study:

  • To investigate the anti-GBM effects of PTC-209, a novel specific inhibitor of BMI-1.
  • To evaluate PTC-209's impact on BMI-1 expression, GSC self-renewal, proliferation, and migration.
  • To explore PTC-209's therapeutic potential in preclinical GBM models.

Main Methods:

  • Assessed BMI-1 expression and H2AK119ub1 levels in GBM and GSCs.
  • Utilized in vitro assays to evaluate PTC-209's effects on glioblastoma cell proliferation, migration, and GSC self-renewal.
  • Performed transcriptomic analyses (TCGA datasets) and Chromatin Immunoprecipitation (ChIP) assays.
  • Evaluated PTC-209 efficacy in a murine orthotopic xenograft model of glioblastoma.

Main Results:

  • PTC-209 significantly downregulated BMI-1 expression and H2AK119ub1 levels in GBM cells.
  • PTC-209 inhibited glioblastoma cell proliferation, migration, and GSC self-renewal in vitro.
  • Transcriptomic analysis revealed PTC-209 reversed BMI-1-associated transcriptional alterations, including derepression of tumor suppressor genes.
  • ChIP assays confirmed decreased H2AK119ub1 enrichment at target tumor suppressor gene promoters upon PTC-209 treatment.
  • PTC-209 significantly attenuated glioblastoma growth in an orthotopic xenograft model.

Conclusions:

  • PTC-209 demonstrates potent anti-GBM activity by inhibiting BMI-1.
  • Targeting BMI-1 with PTC-209 effectively suppresses glioblastoma growth and stem cell properties.
  • This study provides strong preclinical evidence supporting BMI-1 inhibitors as a potential therapeutic strategy for glioblastoma.
Keywords:
BMI-1glioblastomainhibitors

More Related Videos

A 3D Spheroid Model for Glioblastoma07:40

A 3D Spheroid Model for Glioblastoma

Published on: April 9, 2020

16.2K
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

8.3K

Related Concept Videos

Piaget's Stage 1 of Cognitive Development01:14

Piaget's Stage 1 of Cognitive Development

The sensorimotor stage, the initial phase of Jean Piaget's theory of cognitive development, spans the first two years of a child's life. During this period, infants actively engage with their surroundings, building cognitive awareness through direct interaction with the world. This interaction is primarily based on sensory perception and motor actions, allowing infants to gradually understand basic physical properties and predict how objects interact within their environment.
Exploration...
1.8K
Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.2K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
SN1 Reaction: Stereochemistry02:15

SN1 Reaction: Stereochemistry

This lesson provides an in-depth discussion of the stereochemical outcomes in an SN1 reaction.
In the first step of an SN1 reaction, the bond between the electrophilic carbon and the leaving group ionizes to generate the carbocation intermediate. The second step of the mechanism is the nucleophilic attack.
In the formed carbocation, the positively charged carbon is sp2 hybridized with a trigonal planar geometry. As all the three substituents lie on the same plane, a plane of symmetry for the...
10.4K
SN1 Reaction: Kinetics02:05

SN1 Reaction: Kinetics

In an SN2 reaction, the reaction rate depends on both the type of nucleophile and the substrate. A hindered tertiary alkyl halide is practically inert to the SN2 mechanism despite using a strong nucleophile.
However, Sir Christopher Ingold and Edward D. Hughes, who studied the kinetics of various nucleophilic substitution reactions, noticed that a tertiary alkyl halide does undergo a nucleophilic substitution reaction in the presence of a weak nucleophile. While studying the substitution...
9.6K